— Leading telemedicine company expands
offering with hormone-free birth control as GLP-1 medication usage
increases —
— Hello Alpha partnership boosts awareness
of and access to Phexxi for millions of women
—
SAN
DIEGO, June 27, 2024 /PRNewswire/ -- Women's
health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today
announced a new market partnership with Hello Alpha, a telemedicine
company with a medical team specifically trained for a woman's
unique needs, to offer Phexxi® (lactic acid,
citric acid and potassium bitartrate), the non-hormonal
prescription vaginal gel FDA-approved to prevent pregnancy for
those who choose to use an on-demand method of birth
control.
Hello Alpha and Phexxi are changing the narratives around
women's healthcare and offering solutions that complement GLP-1
medications like Ozempic, Wegovy, Mounjaro and Zepbound. These
medications can potentially reduce the effectiveness of birth
control pills during specific intervals within the dosing cycle. To
ensure continued pregnancy prevention, providers on
HelloAlpha.com recommend switching to a non-oral birth control
method or using an additional non-hormonal birth control
method, like Phexxi, alongside oral contraceptives during these
times.
Reinforcing Hello Alpha's commitment to improving healthcare for
women, Gloria Lau, Co-founder &
CEO, says, "This partnership with Evofem helps us offer a safe
and effective birth control option for women, especially those on
GLP-1s and others looking for hormone-free contraceptives."
"Women everywhere deserve access to Phexxi, a non-hormonal,
on-demand contraceptive method that honors their personal
preferences and respects their health autonomy," said Evofem CEO
Saundra Pelletier. "This partnership
between Evofem and Hello Alpha empowers women by offering them that
crucial freedom of choice."
Phexxi is the first and only FDA-approved hormone-free,
locally-acting contraceptive gel. It is applied zero-to-60
minutes before intercourse and works, without hormones, by
maintaining the natural vaginal microbiome with a pH that is
inhospitable to sperm as well as certain bacterial and viral
pathogens.
Hello Alpha, which is available in 50 states plus D.C. and
offers virtual care for more than 100 conditions, continues to
fulfill its mission to bring convenient, affordable, and accessible
medical care, medications, and resources to its patients. To learn
more about Hello Alpha, please
visit https://www.helloalpha.com/.
About Hello Alpha
Hello Alpha is a virtual care solution that specializes in
inclusive, expert care for all by bridging the gaps in women's
health. Through asynchronous messaging, a specially-trained team of
primary care providers delivers whole-person care for more than 100
conditions. at Hello Alpha, every patient partners with a dedicated
provider who offers personalized, preventive care and
evidence-based treatments at every visit. The virtual platform
eliminates the most common barriers to healthcare with asynchronous
messaging that enables patients to get care at any time, from
anywhere, without the need for scheduling appointments, in-person
visits, or busy waiting rooms. Hello Alpha provides patient care
nationwide at a demonstrably lower cost. Founded in 2017, Hello
Alpha serves patients directly and through their
employers.
About Evofem Biosciences
Evofem Biosciences, Inc., is commercializing innovative products
to address unmet needs in women's sexual and reproductive health.
The Company's first FDA-approved product, Phexxi®
(lactic acid, citric acid and potassium bitartrate), is
a hormone-free, on-demand prescription contraceptive vaginal
gel. It comes in a box of 12 pre-filled applicators and is applied
0-60 minutes before each act of sex. Learn more at phexxi.com
and evofem.com.
In December 2023, Evofem entered
into a Merger Agreement with Aditxt, Inc. (Nasdaq: ADTX) under
which Aditxt intends to acquire Evofem. The parties reinstated and
amended the Merger Agreement, as amended, in May 2024, and are working to close the
contemplated transaction in the second half of 2024.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Media Contacts
Kristen Mondshein
kristen@kmmcommunications.com
Amy Raskopf
Chief Business Development Officer
Evofem Biosciences, Inc.
media@evofem.com
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of the safe harbor for forward-looking statements
provided by Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995
including, without limitation, statements regarding the likelihood
of success and anticipated timing to close the contemplated Aditxt
transaction. You are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this press release. Each of these forward-looking statements
involves risks and uncertainties. Important factors that could
cause actual results to differ materially from those discussed or
implied in the forward-looking statements are disclosed in the
Company's SEC filings, including its Annual Report on Form 10-K for
the year ended December 31, 2023 filed with the SEC
on March 27, 2024, Quarterly Report on Form 10-Q for the three
months ended March 31, 2024 filed with the SEC
on May 12, 2024, and any subsequent filings. All
forward-looking statements are expressly qualified in their
entirety by such factors. The Company does not undertake any duty
to update any forward-looking statement except as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hello-alpha-partners-with-evofem-to-offer-phexxi-as-a-hormone-free-contraception-solution-on-its-platform-for-womens-healthcare-302183829.html
SOURCE Evofem Biosciences, Inc.